Highlights
Over 100,000 human dosings with no serious adverse events attributed to the technology
Robust base of potential EMISPHEREŽ delivery agents
- Library of over 2000 EMISPHEREŽ delivery agents
- 6 different EMISPHEREŽ delivery agents advanced to clinical testing; 8 therapeutics tested
- 2 product candidates have been dosed in large study populations for one month or longer
- 4 active INDs
eligenŽ Technology Platform